Loading...

Novacyt

BST:NYZ
Snowflake Description

Adequate balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NYZ
BST
€13M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Novacyt S.A. develops and sells diagnostic products for cancer and infectious diseases. The last earnings update was 61 days ago. More info.


Add to Portfolio Compare Print
NYZ Share Price and Events
7 Day Returns
0%
BST:NYZ
4.8%
DE Biotechs
-1.1%
DE Market
1 Year Returns
-15.3%
BST:NYZ
4.4%
DE Biotechs
-10.7%
DE Market
NYZ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Novacyt (NYZ) 0% 0% 2% -15.3% - -
DE Biotechs 4.8% 2.7% -13.8% 4.4% 61.1% 60.5%
DE Market -1.1% 0.9% -9.3% -10.7% 14.5% 41.2%
1 Year Return vs Industry and Market
  • NYZ underperformed the Biotechs industry which returned 4.4% over the past year.
  • NYZ underperformed the Market in Germany which returned -10.7% over the past year.
Price Volatility
NYZ
Industry
5yr Volatility vs Market

Value

 Is Novacyt undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Novacyt to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Novacyt.

BST:NYZ Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 11.5%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BST:NYZ
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 9.5%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 0.88
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.878 (1 + (1- 33%) (47.91%))
1.16
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.16
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.54% + (1.16 * 9.46%)
11.52%

Discounted Cash Flow Calculation for BST:NYZ using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Novacyt is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

BST:NYZ DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (EUR, Millions) 1.70 2.02 2.39 2.79 3.24
Source Analyst x1 Est @ 19%, capped from 39.83% Est @ 18%, capped from 39.83% Est @ 17%, capped from 39.83% Est @ 16%, capped from 39.83%
Present Value
Discounted (@ 11.52%)
1.52 1.63 1.72 1.81 1.88
Present value of next 5 years cash flows €8.56
BST:NYZ DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= €3.24 × (1 + 0.54%) ÷ (11.52% – 0.54%)
€29.68
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= €29.68 ÷ (1 + 11.52%)5
€17.21
BST:NYZ Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= €8.56 + €17.21
€25.77
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €25.77 / 37.56
€1.01
BST:NYZ Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BST:NYZ represents 1.46552x of ENXTPA:ALNOV
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.46552x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 0.69 x 1.46552
€1.01
Value per share (EUR) From above. €1.01
Current discount Discount to share price of €0.51
= -1 x (€0.51 - €1.01) / €1.01
49.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Novacyt is available for.
Intrinsic value
49%
Share price is €0.51 vs Future cash flow value of €1.01
Current Discount Checks
For Novacyt to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Novacyt's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Novacyt's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Novacyt's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Novacyt's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:NYZ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR €-0.22
ENXTPA:ALNOV Share Price ** ENXTPA (2018-08-29) in EUR €0.35
Europe Biotechs Industry PE Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 27.63x
Germany Market PE Ratio Median Figure of 412 Publicly-Listed Companies 17.68x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Novacyt.

BST:NYZ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:ALNOV Share Price ÷ EPS (both in EUR)

= 0.35 ÷ -0.22

-1.59x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Novacyt is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Novacyt is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Novacyt's expected growth come at a high price?
Raw Data
BST:NYZ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.59x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
88.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 18 Publicly-Listed Biotechs Companies 1.22x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.31x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Novacyt, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Novacyt's assets?
Raw Data
BST:NYZ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR €1.00
ENXTPA:ALNOV Share Price * ENXTPA (2018-08-29) in EUR €0.35
Germany Biotechs Industry PB Ratio Median Figure of 13 Publicly-Listed Biotechs Companies 2.4x
Germany Market PB Ratio Median Figure of 556 Publicly-Listed Companies 1.84x
BST:NYZ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:ALNOV Share Price ÷ Book Value per Share (both in EUR)

= 0.35 ÷ 1.00

0.35x

* Primary Listing of Novacyt.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Novacyt is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Novacyt's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Novacyt has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Novacyt expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
88.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Novacyt expected to grow at an attractive rate?
  • Novacyt's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Novacyt's earnings growth is expected to exceed the Germany market average.
  • Novacyt's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
BST:NYZ Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:NYZ Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 88.9%
BST:NYZ Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 15.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 49.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 25.4%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:NYZ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:NYZ Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 27 2 1 1
2020-12-31 24 2 1 1
2019-12-31 21 2 0 1
2018-12-31 17 1 -1 1
BST:NYZ Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 15 -4 -6
2018-03-31 15 -5 -6
2017-12-31 15 -5 -5
2017-09-30 14 -4 -5
2017-06-30 13 -3 -4
2017-03-31 12 -3 -5
2016-12-31 11 -3 -6
2016-09-30 10 -3 -11
2016-06-30 9 -4 -16
2016-03-31 9 -5 -15
2015-12-31 9 -5 -14
2015-09-30 9 -6 -9

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Novacyt's earnings are expected to grow significantly at over 20% yearly.
  • Novacyt's revenue is expected to grow by 15.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:NYZ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Novacyt Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:NYZ Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31
2018-12-31
BST:NYZ Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30 -0.22
2018-03-31 -0.23
2017-12-31 -0.24
2017-09-30 -0.24
2017-06-30 -0.25
2017-03-31 -0.34
2016-12-31 -0.47
2016-09-30 -1.02
2016-06-30 -1.77
2016-03-31 -1.89
2015-12-31 -2.05
2015-09-30 -1.63

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Novacyt will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Novacyt's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Novacyt has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Novacyt performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Novacyt's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Novacyt does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Novacyt's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Novacyt's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Novacyt's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Novacyt Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:NYZ Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 14.97 -5.57 10.72 0.71
2018-03-31 14.96 -5.51 10.47 0.76
2017-12-31 14.95 -5.44 10.21 0.82
2017-09-30 14.05 -4.67 9.96 0.79
2017-06-30 13.16 -3.90 9.64 0.76
2017-03-31 12.12 -4.80 9.13 0.78
2016-12-31 11.08 -5.71 8.62 0.79
2016-09-30 10.10 -10.70 8.01 0.73
2016-06-30 9.12 -15.69 7.40 0.66
2016-03-31 9.01 -14.80 7.16 0.63
2015-12-31 8.89 -13.91 6.91 0.59
2015-09-30 8.80 -9.50 6.72 0.71
2015-06-30 8.72 -5.09 6.52 0.82
2015-03-31 6.62 -4.50 4.98 0.64
2014-12-31 4.53 -3.91 3.44 0.47
2014-09-30 2.76 -2.48 2.73 0.67
2014-06-30 1.10 -1.04 0.85
2014-03-31 1.15 -1.02 0.86
2013-12-31 1.15 -1.00 1.45 0.44
2013-09-30 1.19 -0.81 0.78
2013-06-30 1.17 -0.63 0.70
2013-03-31 1.14 -0.59 0.61
2012-12-31 1.10 -0.56 0.53
2012-09-30 1.02 -0.67 0.54
2012-06-30 0.94 -0.79 0.54
2012-03-31 0.93 -0.74 0.56
2011-12-31 0.92 -0.68 0.58

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Novacyt has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Novacyt has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Novacyt improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Novacyt's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Novacyt has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Novacyt's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Novacyt's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Novacyt is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Novacyt's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Novacyt's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Novacyt Company Filings, last reported 4 months ago.

BST:NYZ Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 23.02 6.30 2.16
2018-03-31 23.02 6.30 2.16
2017-12-31 24.91 3.89 4.36
2017-09-30 24.91 3.89 4.36
2017-06-30 19.82 8.05 2.59
2017-03-31 19.82 8.05 2.59
2016-12-31 17.77 6.26 2.87
2016-09-30 17.77 6.26 2.87
2016-06-30 16.67 5.76 1.77
2016-03-31 16.67 5.76 1.77
2015-12-31 10.52 3.37 1.69
2015-09-30 10.52 3.37 1.69
2015-06-30 19.88 1.38 1.33
2015-03-31 19.88 1.38 1.33
2014-12-31 20.27 1.03 2.34
2014-09-30 20.27 1.03 2.34
2014-06-30 20.75 1.15 1.57
2014-03-31 20.75 1.15 1.57
2013-12-31 2.25 0.21 1.00
2013-09-30 2.32 0.21 1.00
2013-06-30 2.15 0.73 1.31
2013-03-31 2.15 0.73 1.31
2012-12-31 1.64 1.12 1.67
2012-09-30 1.64 1.12 1.67
2012-06-30 0.03 1.30 0.50
2012-03-31 0.03 1.30 0.50
2011-12-31 -0.89 1.77 0.04
  • Novacyt's level of debt (27.4%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (33.9% vs 27.4% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Novacyt has less than a year of cash runway based on current free cash flow.
  • Novacyt has less than a year of cash runway if free cash flow continues to grow at historical rates of 64.4% each year.
X
Financial health checks
We assess Novacyt's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Novacyt has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Novacyt's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Novacyt dividends.
If you bought €2,000 of Novacyt shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Novacyt's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Novacyt's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:NYZ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 1%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:NYZ Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Novacyt has not reported any payouts.
  • Unable to verify if Novacyt's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Novacyt's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Novacyt has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Novacyt's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Novacyt afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Novacyt has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Novacyt's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Graham Mullis
AGE 55
TENURE AS CEO 4.8 years
CEO Bio

Mr. Graham David Mullis has been the Chief Executive Officer of Novacyt Société Anonyme since 2014. Mr. Mullis served as the Chief Executive Officer of Lab21 Ltd. He served as the President of ClearLab International, a subsidiary of 1 800 Contacts Inc., from 2002 to November 20, 2006 and its Managing Director since 2002. He led the expansion of 1-800 CONTACTS overseas as well as leading Clearlab International. He has more than 10 years experience in leading medical device businesses and 8 years in the contact lens industry. He served as Managing Director of Biocompatibles Hydron and sold the business to CooperVision for $125 million. He launched the Proclear range of contact lenses at Biocompatibles, which is now a major product line for CooperVision , the fourth largest contact lens manufacturer in the world. He serves as a Director of Novacyt Société Anonyme. He served as a Director of Clearlab Pte Ltd. Mr. Mullis holds a Bachelors Degree in Biochemistry & Physiology from Southampton University and an MBA from Warwick Business School.

CEO Compensation
  • Insufficient data for Graham to compare compensation growth.
  • Insufficient data for Graham to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure of the Novacyt management team in years:

1.7
Average Tenure
  • The average tenure for the Novacyt management team is less than 2 years, this suggests a new team.
Management Team

Graham Mullis

TITLE
CEO & Director
AGE
55
TENURE
4.8 yrs

Anthony Dyer

TITLE
CFO, Company Secretary & Director
TENURE
1.7 yrs

Mandy Cowling

TITLE
Corporate & Investor Relations Manager

Wendy Karban

TITLE
Group HR Manager
TENURE
1.8 yrs

Phil Sefton

TITLE
Managing Director of Lab21 Products Division
TENURE
1.6 yrs

Ruth Powell

TITLE
Managing Director of NOVAprep & Lab21 Services

Paul Eros

TITLE
Managing Director of Primer Design

Gérald Ulrich

TITLE
Chief Executive Officer of Business Development

Steve Gibson

TITLE
Group Financial Controller
TENURE
1.6 yrs

Ian Wilde

TITLE
RA & QA Director
TENURE
1.7 yrs
Board of Directors Tenure

Average tenure and age of the Novacyt board of directors in years:

1.4
Average Tenure
55
Average Age
  • The average tenure for the Novacyt board of directors is less than 3 years, this suggests a new board.
Board of Directors

James Wakefield

TITLE
Non-Executive Chairman of the Board

Graham Mullis

TITLE
CEO & Director
AGE
55

Anthony Dyer

TITLE
CFO, Company Secretary & Director
TENURE
1.4 yrs

Andrew John Heath

TITLE
Independent Senior Non-Executive Director
AGE
70
TENURE
3.4 yrs

Juliet Thompson

TITLE
Non-Executive Director
AGE
52
TENURE
1.4 yrs

Jean-Pierre Crinelli

TITLE
Non-Executive Director
COMPENSATION
€120K

David Gardner

TITLE
Member of Scientific Committee

Marco Zonta

TITLE
Member of Scientific Committee

Isabelle Cartier

TITLE
Member of Scientific Committee

Geneviève Bourg-Heckly

TITLE
Member of Scientific Committee
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Novacyt's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Novacyt has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

Company Info

Map
Description

Novacyt S.A. develops and sells diagnostic products for cancer and infectious diseases. The company’s diagnostic products are used in liquid based cytology, oncology, microbiology, haematology, and serology testing. It offers NovaPrep, a liquid based cytology solution that is utilized in the diagnosis of cervical cancer; and clinical laboratory testing services to clinicians, healthcare providers, and patients. The company also develops, manufactures, and distributes diagnostic products for clinical and food laboratories; and manufactures and markets vitro diagnostic tests, as well as diagnostic reagents, test kits, and blood grouping reagents. It serves hospitals and large corporates. The company was founded in 2006 and is based in Vélizy-Villacoublay, France.

Details
Name: Novacyt S.A.
NYZ
Exchange: BST
Founded: 2006
€13,146,308
37,560,882
Website: http://www.novacyt.com
Address: Novacyt S.A.
13 Avenue Morane Saulnier,
Vélizy-Villacoublay,
Ile-de-France, 78140,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA ALNOV Common Stock Euronext Paris FR EUR 12. Oct 2012
BST NYZ Common Stock Boerse-Stuttgart DE EUR 12. Oct 2012
AIM NCYT Common Stock London Stock Exchange AIM Market GB GBP 12. Oct 2012
Number of employees
Current staff
Staff numbers
121
Novacyt employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/11/26 19:32
End of day share price update: 2018/08/29 00:00
Last estimates confirmation: 2018/09/26
Last earnings filing: 2018/09/26
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.